Context Therapeutics Inc. (CNTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$54.5M
Cash & Equivalents
$11.4M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$60M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase1 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | PHASE2 | Active Not Recruiting | 14 |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | PHASE1 | Recruiting | 156 |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | PHASE1 | Recruiting | 70 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-15 | 8-K | Context Therapeutics Inc. (CNTX) (CIK 0001842952) - EX-99.2 | EDGAR |